Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients

[1]  H. Babey,et al.  Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review , 2018, Expert review of anticancer therapy.

[2]  G. Aravantinos,et al.  Anti-PD1/PDL1 induced psoriasis. , 2017, Current problems in cancer.

[3]  C. Bai,et al.  Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma , 2017, Respiratory medicine case reports.

[4]  V. Velcheti,et al.  To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  S. Yokota,et al.  Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report. , 2017, Lung cancer.

[6]  M. Larsabal,et al.  Vitiligo‐like lesions occurring in patients receiving anti‐programmed cell death–1 therapies are clinically and biologically distinct from vitiligo , 2017, Journal of American Academy of Dermatology.

[7]  G. Jeudy,et al.  Anti‐PD1‐induced psoriasis: a study of 21 patients , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  M. Saif,et al.  Incidence and implications of chemotherapy related hand-foot syndrome , 2016, Expert opinion on drug safety.

[9]  K. Kabashima,et al.  Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  P. Hegde,et al.  Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Lacouture,et al.  Dermatological adverse events with taxane chemotherapy , 2016, European Journal of Dermatology.

[12]  J. Wolchok,et al.  Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. , 2016, European journal of cancer.

[13]  K. Byth,et al.  Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.

[14]  Toshiyuki Yamamoto,et al.  Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma. , 2016, Acta dermato-venereologica.

[15]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[16]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[19]  F. Camacho,et al.  The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. , 2015, The oncologist.

[20]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[21]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[22]  Christopher J. Miller,et al.  Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. , 2012, Journal of the American Academy of Dermatology.

[23]  M. Alter,et al.  The hand‐foot‐syndrome associated with medical tumor therapy – classification and management , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[24]  M. Tanioka,et al.  Prospective Study of Ice Gel Pack as Less Expensive Alternative for Prevention of Skin and Nail Toxicity in Patients with Breast Cancer Receiving Docetaxel. , 2009 .

[25]  M. Lacouture,et al.  Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis , 2008, Acta oncologica.

[26]  S. Yashar,et al.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. , 2007, Journal of the American Academy of Dermatology.

[27]  M. Markman.  Managing taxane toxicities , 2003, Supportive Care in Cancer.

[28]  C. Aring,et al.  A CRITICAL REVIEW , 1939, Journal of neurology and psychiatry.

[29]  J. Soria,et al.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.

[30]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.